

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number

WO 2020/215155 A8

(43) International Publication Date
29 October 2020 (29.10.2020)

WIPO | PCT

(51) International Patent Classification:

C07D 413/10 (2006.01) A61P 35/00 (2006.01)
A61K 31/191 (2006.01) C07C 57/15 (2006.01)
A61K 31/5377 (2006.01)

(72) Inventors: **LI, Sze-wan**; 509 Roselawn Avenue, Toronto, Ontario M5N 1K2 (CA). **BRAY, Mark Robert**; 429 Allan Street, Oakville, Ontario L6J 3R1 (CA).

(21) International Application Number:

PCT/CA2020/050535

(74) Agent: **BAKER, James et al.**; Gowling WLG (CANADA) LLP, Suite 2600, 160 Elgin Street, Ottawa, Ontario K1P 1C3 (CA).

(22) International Filing Date:

23 April 2020 (23.04.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/837,858 24 April 2019 (24.04.2019) US



(71) Applicant: **UNIVERSITY HEALTH NETWORK**

[CA/CA]; 190 Elizabeth Street, R. Fraser Elliot Building - Room 1S-417, Toronto, Ontario M5G 2C4 (CA).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: CRYSTAL FORM S4 OF THE PLK4 INHIBITOR (1R,2S)-(E)-2-(3-(4-((CIS-2,6-DIMETHYLMORPHOLINO)METHYL)STYRYL)-1 H-IMIDAZOL-6- YL)-5'-METHOXYSPIRO[CYCLOPROPANE-1,3'-INDOLIN]-2'-ONE FUMARATE

FIG. 1



(57) Abstract: Disclosed is Crystal Form S4 of a fumarate salt of compound (I) represented by the following structural formula: (I) The molar ratio between compound (I) and fumaric acid is 1.0:1.0. Crystal Form S4, 5 characterized by an X-ray powder diffraction pattern which comprises peaks at 6.6°, 9.8°, 16.3°, 21.1°, 28.7°, and 30.2° ± 0.2 in 2θ.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(48) Date of publication of this corrected version:

26 November 2020 (26.11.2020)

(15) Information about Correction:

see Notice of 26 November 2020 (26.11.2020)